ASN's Mission

ASN leads the fight to prevent, treat, and cure kidney diseases throughout the world by educating health professionals and scientists, advancing research and innovation, communicating new knowledge, and advocating for the highest quality care for patients.

learn more

Contact ASN

1401 H St, NW, Ste 900, Washington, DC 20005

email@asn-online.org

202-640-4660

The Latest on Twitter

Kidney Week

Abstract: TH-PO1105

Anti-Mullerian Hormone in Women with CKD

Session Information

Category: CKD (Non-Dialysis)

  • 1902 CKD (Non-Dialysis): Clinical, Outcomes, and Trials

Authors

  • Wiles, Kate, King's College London, London, United Kingdom
  • Wayman, Emma, Guys and St Thomas'' trust, London, United Kingdom
  • Nelson-piercy, Catherine, Guy's & St Thomas' Foundation Trust, London, LoNDON, United Kingdom
  • Lightstone, Liz, Imperial College London, Hammersmith Hospital, London, United Kingdom
  • Chappell, Lucy C., King's College London, London, United Kingdom
  • Bramham, Kate, King's College Hospital, London, United Kingdom
Background

Although CKD is recognised to impact female fertility, underlying pathophysiological mechanisms are poorly understood. Serum concentrations of anti-Mullerian hormone (AMH) are used in women without CKD as a marker of ovarian reserve, which is a key component of female fertility. There are limited data on the utility of serum AMH quantification in women with CKD.

Methods

Serum AMH was quantified by Roche Elecsys AMH assay in 163 women with CKD (30 CKD stage 1, 37 Stage 2, 26 Stage 3a, 31 Stage 3b, 21 Stage 4, 18 Stage 5) seeking pregnancy advice. Values were compared to assay-specific percentiles.

Results

In women with CKD there was no correlation between eGFR and age-corrected AMH centile (r=-0.001, p=0.98). There was a strong correlation between AMH and age (r=-0.5, p<0.0001). Women with CKD had a lower age-corrected AMH concentration compared to women without CKD across all CKD stages (p=<0.0001 to 0.007). The effect of CKD on AMH was greatest for women <35 years (p=0.002-0.03).

Conclusion

Women with CKD have lower levels of serum AMH compared to women without CKD, across all stages of CKD. This suggests that women with CKD have reduced ovarian reserve. The clinical significance of a lower serum AMH, especially in women with CKD <35 years, warrants further investigation. There is no evidence that renal clearance modifies serum AMH concentration.

Age-specific serum AMH concentrations (median ± IQR) in women with CKD (black) compared to controls (grey)

Funding

  • Government Support - Non-U.S.